Niowave Inc. and AstraZeneca are expanding their existing supply agreement to a 10-year commitment to deliver actinium-225, following AstraZeneca’s decision to exercise its option to increase capacity.
Dark Blue Therapeutics was acquired by Amgen.
Niowave expands global agreement with AstraZeneca for 10-year actinium-225 supply
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Reimagine Care and Tampa General Hospital Cancer Institute are teaming up to expand access, increase clinical capacity, and improve cancer care delivery across the Tampa Bay region.
GSK and LTZ Therapeutics, an immunotherapy-focused biotechnology company based in Redwood City, CA, will collaborate to advance the development of novel myeloid cell engagers.
Freenome, an early cancer detection company, and Roche announced a collaboration agreement to commercialize Freenome’s cancer screening technology in international markets.
Microsoft and Qure.ai announced a collaboration that will streamline deployment of Qure.ai solutions to hospitals and health systems across the U.S.
Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, a biotechnology company developing next-generation T cell receptor-based therapies in oncology, announced that they have entered into a collaboration and license agreement to advance a novel in vivo approach to cell therapy for the treatment of solid tumors.
